Compare Stocks → Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars (From GoldenCrest Metals) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADXSNASDAQ:CBIONASDAQ:CNTXNASDAQ:FBRXNASDAQ:PBLA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXSAyala Pharmaceuticals$0.54-5.3%$0.70$0.50▼$1.95$6.15M1.6221,084 shs952 shsCBIOCatalyst Biosciences$0.77$0.19▼$8.69$291.29M1.05763,526 shs32,246 shsCNTXContext Therapeutics$1.41+3.7%$1.23$0.47▼$1.69N/A2.1752,157 shs23,977 shsFBRXForte Biosciences$0.74+2.8%$0.70$0.38▼$1.15$26.20M0.4827,478 shs4,626 shsPBLAPanbela Therapeutics$0.42-10.6%$0.79$0.40▼$477.00$1.65M1.4876,089 shs63,942 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXSAyala Pharmaceuticals-5.59%-10.15%-10.00%-10.00%-58.14%CBIOCatalyst Biosciences0.00%0.00%0.00%0.00%+3,136.08%CNTXContext Therapeutics+3.68%-3.42%+21.03%+48.42%+141.40%FBRXForte Biosciences+2.58%+1.40%+5.45%+5.67%-29.66%PBLAPanbela Therapeutics-11.54%-20.00%-33.33%-88.49%-99.83%Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars (Ad)Big Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.Learn More NowMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACBIOCatalyst BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACNTXContext Therapeutics2.7114 of 5 stars3.55.00.00.03.20.00.6FBRXForte Biosciences3.3058 of 5 stars3.35.00.00.02.22.51.3PBLAPanbela Therapeutics0.6286 of 5 stars3.50.00.00.00.00.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXSAyala Pharmaceuticals2.00HoldN/AN/ACBIOCatalyst BiosciencesN/AN/AN/AN/ACNTXContext Therapeutics3.00Buy$4.00183.69% UpsideFBRXForte Biosciences2.50Moderate Buy$2.75272.33% UpsidePBLAPanbela Therapeutics3.00Buy$500.00118,947.62% UpsideCurrent Analyst RatingsLatest CNTX, PBLA, FBRX, CBIO, and ADXS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/8/2024FBRXForte BiosciencesLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$2.753/27/2024PBLAPanbela TherapeuticsRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/21/2024CNTXContext TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $4.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXSAyala Pharmaceuticals$3.24M1.79N/AN/A($2.27) per share-0.24CBIOCatalyst Biosciences$790K0.00N/AN/A($0.78) per share0.00CNTXContext TherapeuticsN/AN/AN/AN/A$0.74 per shareN/AFBRXForte BiosciencesN/AN/AN/AN/A$0.97 per shareN/APBLAPanbela TherapeuticsN/AN/AN/AN/A($18.37) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXSAyala Pharmaceuticals-$48.07M-$7.98N/A∞N/AN/A-3,967.23%-339.10%5/21/2024 (Estimated)CBIOCatalyst Biosciences-$8.24M-$1.38N/AN/AN/AN/A-364.68%-281.68%N/ACNTXContext Therapeutics-$23.96M-$1.50N/AN/AN/AN/A-115.50%-97.04%5/8/2024 (Estimated)FBRXForte Biosciences-$31.48M-$1.04N/AN/AN/AN/A-94.27%-81.36%5/20/2024 (Estimated)PBLAPanbela Therapeutics-$25.26M-$669.09N/AN/AN/AN/A-70,194.55%-172.92%5/2/2024 (Estimated)Latest CNTX, PBLA, FBRX, CBIO, and ADXS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2024Q4 2023PBLAPanbela Therapeutics-$24.34-$65.90-$41.56-$65.90N/AN/A3/21/2024Q4 2023CNTXContext Therapeutics-$0.35-$0.42-$0.07-$0.42N/AN/A3/18/2024Q4 2023FBRXForte BiosciencesN/A-$0.04-$0.04-$0.04N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXSAyala PharmaceuticalsN/AN/AN/AN/AN/ACBIOCatalyst BiosciencesN/AN/AN/AN/AN/ACNTXContext TherapeuticsN/AN/AN/AN/AN/AFBRXForte BiosciencesN/AN/AN/AN/AN/APBLAPanbela TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXSAyala PharmaceuticalsN/A0.300.30CBIOCatalyst BiosciencesN/A2.882.88CNTXContext TherapeuticsN/A3.833.83FBRXForte BiosciencesN/A10.4510.45PBLAPanbela TherapeuticsN/A0.250.25OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXSAyala Pharmaceuticals7.18%CBIOCatalyst Biosciences5.98%CNTXContext Therapeutics14.03%FBRXForte Biosciences77.63%PBLAPanbela Therapeutics4.37%Insider OwnershipCompanyInsider OwnershipADXSAyala Pharmaceuticals0.63%CBIOCatalyst Biosciences2.92%CNTXContext Therapeutics9.38%FBRXForte Biosciences10.53%PBLAPanbela Therapeutics0.01%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADXSAyala PharmaceuticalsN/A10.75 million10.68 millionNot OptionableCBIOCatalyst Biosciences737.98 million36.87 millionOptionableCNTXContext Therapeutics5N/AN/ANot OptionableFBRXForte Biosciences936.40 million32.56 millionOptionablePBLAPanbela Therapeutics63.48 million3.48 millionNot OptionableCNTX, PBLA, FBRX, CBIO, and ADXS HeadlinesSourceHeadlinePanbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025globenewswire.com - April 22 at 8:00 AMPanbela Applies to List on CBOEmarketwatch.com - April 18 at 6:11 PMPanbela Announces Poster Presentation at American Association for Cancer Research:globenewswire.com - April 18 at 8:00 AMPanbela Therapeutics, Inc.: Panbela Announces Transfer to OTCQB Marketfinanznachrichten.de - April 17 at 9:49 AMPanbela Announces Transfer to OTCQB Marketfinance.yahoo.com - April 16 at 7:24 PMRecap: Panbela Therapeutics Q4 Earningsbenzinga.com - March 28 at 7:34 PMPanbela Therapeutics, Inc. (PBLA) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 28 at 2:34 PMPanbela Therapeutics, Inc. (NASDAQ:PBLA) Q4 2023 Earnings Call Transcriptmsn.com - March 27 at 3:10 PMPanbela Therapeutics, Inc.: Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Resultsfinanznachrichten.de - March 27 at 10:09 AMPanbela Provides Business Update and Reports Q4 and FY 2024 Financial Resultsglobenewswire.com - March 26 at 4:10 PMEarnings Preview: Panbela Therapeuticsbenzinga.com - March 26 at 1:12 AMPBLA Panbela Therapeutics, Inc.seekingalpha.com - March 22 at 11:01 PMPanbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024globenewswire.com - March 12 at 4:15 PMTop 4 Health Care Stocks That Are Preparing To Pump This Monthmsn.com - February 23 at 11:40 PMTop 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)benzinga.com - February 23 at 7:50 AMPanbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirementsfinance.yahoo.com - February 15 at 11:37 AMPanbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirementsglobenewswire.com - February 15 at 8:00 AM10% Owner GOLDMAN SACHS GROUP INC sale 72,874 shares of Panbela Therapeutics Inc. [PBLA]knoxdaily.com - February 1 at 8:01 PMPanbela Announces Closing of Approximately $9.0 Million Public Offeringfinance.yahoo.com - February 1 at 9:59 AMPanbela Therapeutics Inc (PBLA)investing.com - January 31 at 8:53 AMPanbela Therapeutics, Inc.: Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)finanznachrichten.de - January 30 at 3:23 PMWhat's Going On With Panbela Therapeutics Stock Today?benzinga.com - January 30 at 10:23 AMAcceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)finance.yahoo.com - January 30 at 10:23 AMPanbela Therapeutics, Processa Pharmaceuticals among healthcare moversmsn.com - January 29 at 1:25 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAyala PharmaceuticalsNASDAQ:ADXSAyala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.Catalyst BiosciencesNASDAQ:CBIOCatalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.Context TherapeuticsNASDAQ:CNTXContext Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Forte BiosciencesNASDAQ:FBRXForte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.Panbela TherapeuticsNASDAQ:PBLAPanbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase. It has a research agreement with the Johns Hopkins University School of Medicine for the development of Panbela's investigative agent ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.